Market Access News | pharmaphorum

News

Janssen J&J Johnson and Johnson pharmaceutical companies

NICE makes J&J's Tremfya more accessible in England and Wale...

NICE has updated its recommendations for NHS use of Johnson & Johnson's IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible fo

News

BMS' Opdivo gets NHS use as adjuvant bladder cancer therapy

NICE has recommended routine use of Bristol-Myers Squibb's Opdivo for the adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of bladder cancer.

News

FDA backs pharmacist prescribing of Paxlovid for COVID

Some patients with COVID-19 will be able to get easier access to Pfizer's oral antiviral therapy Paxlovid, after the FDA ruled that pharmacists would be able to prescribe the drug.

News

Eisai/Biogen could get FDA verdict on new Alzheimer's drug b...

The FDA has started an accelerated review of Eisai and Biogen's a new amyloid-targeting antibody lecanemab for Alzheimer's disease, with a 6 January deadline that keep them ahead of closest

News

FDA to decide on Roche's lymphoma drug Lunsumio before year-...

The FDA has granted a priority review to Roche's T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December.

News

FDA rejection of Spero's tebipenem 'raises resistance threat...

The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic re

NICE makes J&J's Tremfya more accessible in England and Wale...

BMS' Opdivo gets NHS use as adjuvant bladder cancer therapy

FDA backs pharmacist prescribing of Paxlovid for COVID

Eisai/Biogen could get FDA verdict on new Alzheimer's drug b...

FDA to decide on Roche's lymphoma drug Lunsumio before year-...

FDA rejection of Spero's tebipenem 'raises resistance threat...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks